AWHL (Aspira Womens Health) Moat Score: 3/10 (As of Jul. 02, 2026)


AWHL Aspira Womens Health Inc AWHL
36 GF Score
Price $0.42
GF Value $0.28
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Aspira Womens Health Moat Score?

Aspira Womens Health AWHL +7.07% 36 Moat Score is 3 as of Jul. 02, 2026. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Aspira Womens Health ranks better than 76.85% on this metric.

Aspira Womens Health has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Aspira Womens Health has No Moat: Aspira Womens Health Inc has very weak competitive advantages. It lacks market leadership, strong brand strength, and significant customer switching costs, making its position in the healthcare sector transient and vulnerable to competition.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Aspira Womens Health might have No Moat - Very weak/transient advantages.

Aspira Womens Health  (OTCPK:AWHL) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Aspira Womens Health Moat Score Related Terms

AWHL vs MDXH, BIOQ, XWEL: Moat Score Comparison

For the Diagnostics & Research subindustry, Aspira Womens Health's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspira Womens Health Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Moat Score distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Moat Score falls into.


AWHL
36GF Score
Aspira Womens Health Inc AWHL
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Aspira Womens Health (AWHL) has a Moat Score of 3 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Aspira Womens Health ranks #50 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 23.1%.
Is Aspira Womens Health's Moat Score too high?
Aspira Womens Health's current Moat Score is 3. Based on the distribution chart, Aspira Womens Health ranks #50 out of 216 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's Moat Score compare to MDXH and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #50 out of 216 companies for Moat Score. This places Aspira Womens Health in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Aspira Womens Health's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.42 — trading 50% above its estimated fair value. The current Moat Score is 3. Aspira Womens Health's overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current Moat Score is 3 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspira Womens Health (AWHL) Overvalued in 2026?

Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued. The current stock price of $0.42 is trading 50% above its estimated GF Value™ of $0.28. GuruFocus considers Aspira Womens Health to be Significantly Overvalued.

Key valuation signals for AWHL:

  • Moat Score: 3
  • GF Value™: $0.28 vs. price of $0.42 (50% above fair value)
  • GF Score™: 36/100 with 8 warning signs

No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspira Womens Health Business Description

Address 12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
36GF Score

Get the complete analysis for AWHL

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price
$0.28
GF Value